financetom
Business
financetom
/
Business
/
ReconAfrica Signs Production Sharing Contract, JV for Offshore Block in Gabon
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ReconAfrica Signs Production Sharing Contract, JV for Offshore Block in Gabon
Sep 9, 2025 7:48 AM

10:37 AM EDT, 09/09/2025 (MT Newswires) -- Reconnaissance Energy Africa ( RECAF ) said Tuesday it signed a production sharing contract (PSC) and joint venture agreement with Record Resources (TSXV: REC), the Republic of Gabon and Gabon Oil Company (GOC).

The PSC covers exploration, appraisal, development and production of oil and gas on Gabon offshore Block C-7, renamed Ngulu. Under the JV terms, Recon will operate the block with a 55% interest, Record will hold 20%, GOC 15% and the Republic of Gabon 10% on a carried basis.

"The exploration inventory in Gabon contains play types analogous to the Gulf of Mexico deepwater plays," chief executive Brian Reinsborough said. "We plan to deploy Gulf of Mexico style exploration using state-of-the-art reprocessing to reduce risk and increase our chance of success on exploration drilling in this underexplored region of Gabon."

The PSC area covers 1,214 square kilometers, equivalent to about 54 Gulf of Mexico blocks, in shallow water offshore central Gabon. The Ngulu block lies on trend with producing fields ranging from 38 million to 250 million barrels. The company believes near-term oil production potential could provide cashflow to fund exploration growth.

Recon said the Loba field, discovered in 1976 with 140 meters of gross pay, provides low-risk appraisal and development potential, with possible output of about 20,000 barrels per day.

The company committed during the initial four-year term to conduct geological and geophysical studies, reprocess 3D seismic data and drill one well. Recon said there is significant exploration upside across 28 mapped prospects.

Shares of the company were last seen down 3.2% at $0.60 on the TSX Venture Exchange.

Price: 0.60, Change: -0.02, Percent Change: -3.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bunge's Brazil gradually resuming operations in Rio Grande
Bunge's Brazil gradually resuming operations in Rio Grande
May 20, 2024
SAO PAULO, May 20 (Reuters) - The Brazilian unit of U.S.-based grain trader Bunge said on Monday it is gradually resuming operations in the town of Rio Grande, where it operates a port terminal and a soy crushing unit in southern Brazil. Grain reception and loading operations at Bunge's Rio Grande port has resumed while its local soy crushing unit...
--Chemed Maintains Quarterly Dividend at $0.40 Per Share, Payable June 18 to Shareholders of Record on May 30
--Chemed Maintains Quarterly Dividend at $0.40 Per Share, Payable June 18 to Shareholders of Record on May 30
May 20, 2024
03:52 PM EDT, 05/20/2024 (MT Newswires) -- Price: 562.72, Change: -2.80, Percent Change: -0.50 ...
HP Stock Is Rising Monday: What's Going On?
HP Stock Is Rising Monday: What's Going On?
May 20, 2024
HP Inc. ( HPQ ) is stirring up investor interest Monday afternoon with notable movement in its stock price. What To Know: HP unveiled a new class of next-generation AI PCs at Microsoft Corp’s AI Vision Event on Monday. The unveiling of the HP OmniBook X AI PC and HP EliteBook Ultra AI PC marked a significant step forward in...
Why Is Dyne Therapeutics Stock Soaring On Monday?
Why Is Dyne Therapeutics Stock Soaring On Monday?
May 20, 2024
Monday, Dyne Therapeutics Inc ( DYN ) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.  Earlier this year, Dyne Therapeutics ( DYN ) released initial clinical data from both trials. In...
Copyright 2023-2026 - www.financetom.com All Rights Reserved